Zai Lab (09688.HK) total revenue for the third quarter reached US$108.2 million.

Zhitong Finance APP News, Zai Lab (09688.HK) announced that total revenue for the third quarter of 2026 was US$108.2 million, compared with US$116.1 million in the same period of 2025. Net product revenue for the third quarter of 2026 was US$107.6 million, compared with US$115.4 million in the same period of 2025. Net product revenue increased 2% quarter-over-quarter, primarily driven by Nuzyra (benefiting from improved market coverage and penetration) and xanomeline trospium chloride (launched in June 2026), partially offset by a decline in Tumor Treating Fields revenue due to changes in the competitive landscape for glioblastoma.